Meeting Report

Juvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium

Rebecca J. Chan a, Todd Cooper b, Christian P. Kratz c, Brian Weiss d, Mignon L. Loh e,*

a Departments of Pediatrics, The Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
b Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
c Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany
d Department of Pediatrics, Division of Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA
e Department of Pediatrics, University of California, 513 Parnassus Ave, Box 0519, San Francisco, CA 941143, USA

Received 15 August 2008; received in revised form 15 August 2008; accepted 19 August 2008

Abstract

Juvenile myelomonocytic leukemia (JMML) is an aggressive childhood myeloproliferative disorder characterized by the overproduction of myelomonocytic cells. JMML incidence approaches 1.2/million persons in the United States (Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995). Although rare, JMML is innately informative as the molecular genetics of this disease implicates hyperactive Ras as an essential initiating event. Given that Ras is one of the most frequently mutated oncogenes in human cancer, findings from this disease are applicable to more genetically diverse and complex adult leukemias. The JMML Foundation (www.jmmlfoundation.org) was founded by parent advocates dedicated to finding a cure for this disease. They work to bring investigators together in a collaborative manner. This article summarizes key presentations from The Second International JMML Symposium, on 7–8 December 2007 in Atlanta, GA. A list of all participants is in Supplementary Table.

Keywords: Juvenile myelomonocytic leukemia (JMML); RAS; PTPN11; NF1; Therapy; Diagnosis

1. Introduction

Juvenile myelomonocytic leukemia (JMML) is a lethal myeloproliferative disease (MPD) of young childhood characterized clinically by overproduction of myelomonocytic cells and by the in vitro phenotype of hematopoietic progenitor hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF) [1,2]. In contrast to normal subjects, the morphological composition of progenitor colonies from JMML patients is predominantly macrophages and monocytes [3,4]. It is notable, however, that progenitor colonies from JMML patients contain monocytic cells along the full spectrum of differentiation, including blast forms, promonocytes, monocytes, and macrophages. This distinct characteristic indicates that JMML is not a disease induced by a complete block in differentiation as observed in acute leukemias, but instead results from shunting of hematopoietic differentiation toward the monocytic pathway, similar to increased granulocytic differentiation in the chronic phase of chronic myeloid leukemia (Fig. 1). In addition to monocytic cell overproduction, patients often present with anemia, thrombocytopenia, and 50% of patients also present with elevated fetal hemoglobin, hemoglobin F (Hgb F) [5]. JMML patients can progress to blast crisis, usually with French-American-British (FAB) M4 or M5 morphology, but more frequently succumb to disease due to tissue infiltration of myeloid cells. Standard cytotoxic chemotherapy in JMML is ineffective, producing few durable remissions [6].

* Corresponding author. Tel.: +1 415 514 0853; fax: +1 415 502 5127. E-mail address: LohM@peds.ucsf.edu (M.L. Loh).

0145-2126/$ – see front matter © 2008 Elsevier Ltd. All rights reserved.
doi:10.1016/j.leukres.2008.08.022

2. Molecular genetics

2.1. Learning from patients

The clinical presentation of JMML has provided clinicians and researchers with crucial clues to the molecular aberrancies underlying this rare disease. First, young children with the congenital disorder, neurofibromatosis type 1 (NF1), have an increased incidence of malignant myeloid disorders, including JMML [16,17]. The characterisation of neurofibromin (encoded by NF1) as a Ras GTPase activating protein (GAP) [32,33] that normally restricts Ras activation suggested that dysregulation of Ras activation contributes to the pathological process of JMML. Furthermore, the finding that loss-of-function NF1 mutations are mostly non-overlapping with gain-of-function KRAS and NRAS mutations in JMML patients strongly implicates Ras hyperactivation in JMML [12]. Similarly, the predisposition of some children with Noonan syndrome (NS), 50% of whom bear germline PTPN11 mutations [20,34], to develop a JMML-like MPD [18,19] prompted investigators to test children with non-syndromic, de novo JMML for somatic PTPN11 mutations [13–15]. Taken together, 35% of patients have gain-of-function mutations in PTPN11, 35% gain-of-function mutations in NRAS or KRAS, and another 15% have clinical NF1. Rarely, patients have been described to harbor dual mutations in these molecules and there is active investigation to determine if these mutations exist in separate hematopoietic progenitor cells.

2.2. Correlating genotype with phenotype

For potential improved prognostication of JMML, investigators are performing studies to examine if NF1, RAS, and PTPN11 mutational status yields predictive clinical course information for patients. Increased age (>4 years), increased fetal hemoglobin (HgF, >15%), and reduced platelets (<33,000/μL) consistently correlate with a poor outcome (reduced event free survival and overall survival) of JMML patients following allogeneic HSCT; however, the potential correlation of gene mutational status with clinical outcome is unknown. Matsuda and colleagues made the observation that three children with JMML bearing mutations of NRAS or KRAS (2 with NRASG12S and 1 with KRASG12S) demonstrated a mild clinical course with spontaneous remission without HSCT [35]. These findings suggested that certain RAS alleles may correlate with favorable clinical outcomes. However, in a follow-up study, Flotho and associates were unable to confirm that certain RAS alleles are associated with long-term survival in the absence of HSCT [36]. In another study directed at examining the hypothesis that mutational status may correlate with JMML clinical features and prognosis, Kojima and colleagues evaluated the clinical course and laboratory findings of 49 JMML patients, 32 of whom bore mutations in NF1, KRAS, NRAS, or PTPN11. In univariate analyses, PTPN11 mutations were associated with
Fig. 2. Schematic diagram showing ligand-stimulated Ras activation, the Ras-Erk pathway, and the gene mutations found to date contributing to the neuro-cardio-facio-cutaneous congenital disorders and JMML. NL/MGCL: Noonan-like/multiple giant cell lesion; CFC: cardio-facio-cutaneous; JMML: juvenile myelomonocytic leukemia.

older age at diagnosis (>24 months), increased HgF (>10%), reduced overall survival, and, importantly, appeared to be an unfavorable prognostic factor predicting relapse following transplantation [37].

2.3. Designing accurate murine models

Definition of key mutated genes in JMML has permitted basic researchers to develop in vivo models of JMML. Hematopoietic progenitors from Nf1−/− and KrasG12D mice demonstrate elevated Ras-GTP, hypersensitivity to GM-CSF, and produce MPD in vivo [38–40]. Conditional inactivation of Nf1 in hematopoietic cells induces MPD with 100% penetrance, hypersensitivity to GM-CSF, and resistance to apoptosis [41]. Likewise, wild type mice reconstituted with fetal liver progenitors from Nf1−/− animals develop MPD similar to JMML which is attenuated in mice lacking GM-CSF [42]. Currently, Braun, Shannon, and others are utilizing KrasG12D mice and mice bearing a conditional deletion allele of Ptpn11 [43] to examine the question of whether Shp2 functions upstream, downstream, or in parallel to Ras in GM-CSF-stimulated signaling, in normal hematopoiesis, and in the pathogenesis of JMML. Their studies indicate that Shp2 functions at least partly downstream or parallel to Ras in hematopoietic stem cells, similar to that observed in Drosophila [44], although more recent results indicate that Ras is downstream of Shp2 in myeloid progenitors (B. Braun, personal communication). Furthermore, while Shp2 phosphatase activity is needed for leukemogenesis, it is dispensable for normal hematopoiesis [45–47]. An additional in vivo model of JMML was developed by Neel and colleagues using retroviral transduction of murine hematopoietic stem cells with gain-of-function Ptpn11 mutants (Shp2E61Y and Shp2E76K) followed by transplantation into lethally irradiated recipients [46]. Similar to mice bearing loss-of-function Nf1 or gain-of-function Kras mutations, mice expressing gain-of-function Shp2 also developed MPD in vivo [46]. To remove some of the uncertainty of variable disease onset following adoptive transfer of retrovirally transduced cells, however, Chan and Neel have developed a conditional knock-in allele of Shp2D61Y (LSL-Shp2D61Y) [48]. Consistent with results obtained from mice transplanted with mutant Shp2-expressing cells, the LSL-Shp2D61Y mice develop MPD by 5–7 months following induced expression of Shp2D61Y. However, unlike the transplanted mice, the LSL-Shp2D61Y mice also develop anemia, thus recapitulating more closely the phenotype commonly observed in JMML patients [48]. Using these sophisticated genetic in vivo models, researchers continue to seek unique and novel molecules that can be rationally targeted for improved therapeutic tactics in JMML.

3. Advances in JMML diagnosis and surveillance

3.1. Redefining the criteria for diagnosis

In addition to the basic science studies that are being expanded, improved diagnostic, prognostic, and relapse detection techniques are currently under development. The current diagnostic criteria for JMML include absolute monocyte count > 1000/µL, <20% blasts in the bone marrow, and absence of the BCR-ABL fusion gene plus two of the four following criteria: (1) circulating myeloid precursors; (2) WBC > 10,000/µL; (3) increased fetal hemoglobin (HbF) for age; or (4) hematopoietic progenitor hypersensitivity to GM-CSF (Table 1). However, based on the identification of
multiple gene mutations in JMML, alternative diagnostic criteria were devised at the JMML Working Group Meeting in Geneva, Switzerland in September, 2006. These proposed criteria have incorporated \textit{NF1}, \textit{RAS}, and \textit{PTPN11} mutational status or the identification of monosomy 7 into the diagnostic assessment (Table 2).

While hematopoietic progenitor hypersensitivity to GM-CSF has traditionally been used as a minor diagnostic criteria for JMML (Table 1), it is a time-consuming and cumbersome assay to perform using conventional cell culture methods. To address this problem, Kotecha, Nolan, and Loh have evaluated the correlation between GM-CSF-stimulated activation of STAT5, detected using phosphoflow cytometry for phospho-STAT5, with GM-CSF-stimulated hematopoietic progenitor colony growth in JMML patients and healthy controls [49]. The GM-CSF-stimulated phospho-STAT5 assay yielded results very similar to that of the traditional GM-CSF-stimulated hematopoietic progenitor assay, providing a novel diagnostic test that is 95% specific and 91% sensitive to therapy and detection of minimal residual disease in JMML, which may be particularly relevant in patients receiving experimental or conventional chemotherapeutic agents.

### 3.2. Redefining the criteria for response

In the past, response to chemotherapy for JMML has been defined using a complicated assessment of white blood cell count, platelet count, and organomegaly (Table 3a). However, in 2006, the International JMML Working Group meeting in Geneva discussed this topic. First, there was general agreement on the importance of developing new agents that may be biologically active in the treatment of JMML. The goals of testing these agents would be to determine the biologic or clinical activity as well as to define the toxicity profile. Therefore, the group advocated simplification of the criteria and removal of the marginal response. Also, in order to evaluate new agents in an upfront window it was important for patients to have measurable disease. Therefore, the group agreed that in order to be enrolled on future clinical trials to evaluate new agents, patients would need to exhibit a WBC count > 20,000/\mu L and splenomegaly greater than 2 cm below the costal margin. Clinical findings from the European Working Group on MDS in Childhood (EWOG-MDS) and the North American JMML Project (NAJP) indicated that spleen size and WBC count were the most significant response parameters to evaluate during pre-transplant chemotherapy. Dr. Cooper reviewed these definitions during the 2007 Symposium, as summarized in Table 3b. Following allogeneic stem cell transplantation, response to therapy and detection of minimal residual disease can be assessed by following donor chimerism; however, no good method exists for tracking molecular responses to therapy in children who receive traditional chemotherapy or experimental therapies prior to transplantation. To address these limitations, Archambeault and Loh have developed a novel method of detecting minimal residual disease to

### Table 1

**Current JMML diagnostic criteria.**

<table>
<thead>
<tr>
<th>All of the following</th>
<th>At least 2 of the following</th>
</tr>
</thead>
<tbody>
<tr>
<td>Absence of the (\text{t}(9;22)) \text{BCR/ABL} fusion gene</td>
<td>Circulating myeloid precursors</td>
</tr>
<tr>
<td>Absolute monocyte count &gt; 1000/\mu L</td>
<td>White blood count &gt; 10,000/\mu L</td>
</tr>
<tr>
<td>&lt;20% blasts in the bone marrow</td>
<td>Increased fetal hemoglobin (HgF)</td>
</tr>
<tr>
<td>GM-CSF hypersensitivity</td>
<td></td>
</tr>
</tbody>
</table>

### Table 2

**Proposed JMML diagnostic criteria.**

<table>
<thead>
<tr>
<th>Category 1</th>
<th>Category 2</th>
<th>Category 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>All of the following</td>
<td>At least 1 of the following</td>
<td>At least 2 of the following</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>Somatic mutation in RAS or PTPN11</td>
<td>Circulating myeloid precursors</td>
</tr>
<tr>
<td>Absolute monocyte count &gt; 1000/\mu L</td>
<td>Clinical diagnosis of NF1 or (\text{NF1}) gene mutation</td>
<td>WBC &gt; 10,000/\mu L</td>
</tr>
<tr>
<td>Blasts in PB/BM &lt; 20%</td>
<td>Monosomy 7</td>
<td>Increased fetal hemoglobin (HgF) for age</td>
</tr>
<tr>
<td>Absence of the (\text{t}(9;22)) \text{BCR/ABL} fusion gene</td>
<td></td>
<td>Clonal cytogenetic abnormality excluding monosomy 7</td>
</tr>
<tr>
<td>Age less than 13 years</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table 3a

**Current JMML response criteria.**

<table>
<thead>
<tr>
<th>WBC</th>
<th>Organomegaly</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response</td>
<td>Normal</td>
</tr>
<tr>
<td>Partial response</td>
<td>&gt;50% reduction</td>
</tr>
<tr>
<td>Marginal response</td>
<td>&gt;25% ≤ 50% reduction</td>
</tr>
<tr>
<td>Stable disease</td>
<td>≤25% reduction</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>&gt;25% increase</td>
</tr>
</tbody>
</table>

### Table 3b

**Proposed JMML response criteria.**

<table>
<thead>
<tr>
<th>Complete clinical response</th>
<th>Partial clinical response</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood count</td>
<td>&lt;20 K</td>
</tr>
<tr>
<td>Splenomegaly</td>
<td>Normalization of spleen size</td>
</tr>
</tbody>
</table>

follow response to therapy by merging TaqMan chemistry with a mismatched amplification mutation assay (MAMA), referred to as TaqMAMA [50]. This method is based on the preferential amplification of the mutant allele compared to the wild type allele. These assays were developed to follow the most common PTPN11 (226G > A, 214G > A, 227A > G, and 1508G > C), KRAS (38G > A and 35G > A), and NRAS (38G > A and 37G > C) mutations found in JMML, were adequately sensitive to detect the mutant alleles, and were very specific for seven of the eight mutant alleles examined. Importantly, detection of the mutant allele from peripheral blood cells correlated very well with detection from bone marrow cells, suggesting that tracking disease burden by peripheral blood draws rather than by multiple bone marrow aspirations is feasible using this method. Furthermore, the TaqMAMA method detected disease relapse either earlier or simultaneous to disease relapse detection determined by the conventional autologous cell chimerism method. Collectively, these findings suggest that the TaqMAMA methodology provides a potentially powerful tool for following response to upfront novel therapies and for detecting minimal residual disease following transplantation in children with JMML.

4. Current therapy

Unfortunately, JMML has proved to be resistant to essentially all chemotherapy regimens examined including single agents as well as combination chemotherapy typically utilized in acute leukemias [6]. The only curative therapy is allogeneic stem cell transplantation which is able to cure approximately 50% of patients; however, the leading cause of death following transplantation continues to be leukemia relapse [7,51,52]. Some patients who suffer from relapse are cured from a secondary allogeneic transplant [53]. Two main retrospective studies have been published evaluating the efficacy of allogeneic transplantation in JMML. First, the Japanese Society of Pediatric Hematology (JSPH) published a series of 27 patients diagnosed with JMML based on criteria outlined by the International JMML Working Group. Although the preparative regimens and graft sources varied widely, this retrospective evaluation demonstrated an overall survival of 57.9% and an event free survival of 54.2% at 4 years after allogeneic transplantation [54]. A second trial with 100 children conducted by the European Working Group on Childhood MDS (EWOG-MDS) and the European Blood and Marrow Transplantation (EMBT) Group used a preparative regimen consisting of busulfan (16–20 mg/kg x 4 consecutive days), cyclophosphamide (60 mg/kg x 2 doses), and melphalan (140 mg/m², single dose). Graft sources varied from bone marrow, peripheral blood, or cord blood. Similar to the JSPH study, children undergoing allogeneic transplantation achieved an overall survival of 64% and event free survival of 52% [7]. Other analyses from this study revealed no significant difference in event free survival between children receiving grafts from siblings v. unrelated donors or between splenectomized v. non-splenectomized patients at the time of transplant. Event free survival was significantly increased in males and in children < 2 years of age at the time of JMML diagnosis, consistent with the finding of increased survival in children < 1 year at the time of diagnosis demonstrated in the JSPH study. However, findings from the EWOG/EBMT trial revealed no difference in event free survival between patients with normal vs. karyotypic abnormalities while the JSPH trial demonstrated a significant reduction in overall survival in patients with karyotypic abnormalities [7,54]. Two subsequent studies have been performed by the JPHS. Patients on trial MDS 99 received busulfan (140 mg/m² x 4 doses), cyclophosphamide (60 mg/kg x 2 doses), and high dose cytarabine (3 g/m² x 4 doses). In this study, the investigators observed a 50% disease free survival. Upon subgroup analysis, disease free survival was better in individuals with a normal karyotype as well as patients experiencing either acute or chronic graft vs. host disease. In a second trial, a conditioning regimen including busulfan (140 mg/m² x 4 doses), fludarabine (30 mg/m² x 4 doses), and LPAM (90 mg/m² x 2 doses) produced a disease free survival of 75% at 6 years following transplant. In short, although a rigorous intervention, allogeneic stem cell transplantation provides a real chance of cure for children suffering from JMML. However, scientists and clinicians continue to study JMML aggressively in basic research labs in a concerted effort to define novel therapeutic targets and to develop effective, less toxic, therapeutic interventions.

5. Experimental therapies

Although allogeneic transplant does provide a curative modality for JMML, there are significant morbidities associated with this aggressive intervention; thus, improved and less toxic therapies are currently under evaluation. Given the importance of Ras hyperactivation in the pathophysiology of JMML, agents designed to target Ras activity are being evaluated. Ras is first activated at the cell membrane via the addition of a farnesyl group to the newly translated protein. Farnesyl transferase inhibitors (FTIs) prevent Ras translocation to the plasma membrane by inhibiting Ras isoprenylation, thus leading to downregulation of Ras-activated cellular pathways [55]. It was thus hypothesized that inhibiting farnesyl transferase activity may inhibit Ras activation, despite the knowledge that an alternative pathway to Ras activation occurs by geranylgeranylation. In vitro studies demonstrated significant growth inhibition of JMML patient samples by the peptidomimetic FTIs, L-739,749 and L-744,832 [56]. Based on these in vitro findings, Castleberry, Emanuel, and co-workers recently completed a phase II window clinical trial (AML0122) designed to evaluate the dosing and potential effectiveness of R115777, a non-peptidomimetic FTI, in newly diagnosed, previously untreated JMML patients.
Patients received two courses of R115777 (200 mg/m² or 300 mg/m² by mouth each day for 21 days) followed by two courses of cis-retinoic acid, cytarabine, and fludarabine, splenectomy, and allogeneic transplantation. Following administration of R115777, response to therapy was assessed by white blood cell counts and organomegaly based on current guidelines for JMML response criteria (Table 3a). A total of 11 patients received 200 mg/m² for two courses. The therapy was well tolerated and six patients achieved a partial response, one patient achieved a marginal response, two maintained stable disease, and one demonstrated progressive disease. A total of 36 patients received 300 mg/m² for two courses. Among this group, two patients achieved a complete remission, 14 achieved a partial response, seven a marginal response, two maintained stable disease, and three demonstrated progressive disease. Taken together, 81% of patients demonstrated a clinical response to R115777 (including all with complete, partial, and marginal responses at both doses administered). The main toxicity induced by R115777 was bone marrow suppression. Response or lack of response to the drug was not correlated with patient mutational status (NF1, KRAS, NRAS, PTPN11, or monosomy 7), nor was inhibition of farnesyl transferase activity as measured by the surrogate prenylation of the heat shock molecule, HDJ2 [57]. Unfortunately, preliminary findings presented at the 2nd International JMML Symposium indicated that event-free survival did not appear to be favorably impacted by the use of R115777 compared to the outcomes of other trials; however, this trial is ongoing and the data has not matured. Thus, the event-free survival and overall survival of patients receiving R115777 prior to allogeneic transplantation continues to be evaluated.

In addition to directly targeting Ras, agents that target Ras effectors within the MAPK cascade, such as RAF-1 and MEK, are also being evaluated in myeloid leukemias. Previous in vitro and in vivo studies demonstrated that treatment of JMML cells with a DNA enzyme designed to target RAF1 mRNA, thus reducing RAF1 expression, resulted in reduced hypersensitivity of JMML cells to GM-CSF and reduced mortality of NOD-SCID mice transplanted with JMML cells, respectively [58]. Based on these findings, a phase II window clinical trial is under development to evaluate response rate and acute toxicity of JMML patients to sorafenib (BAY 43-9006), a RAF kinase inhibitor.

Additionally, Lauchle and colleagues have evaluated the effect of CI-1040, a selective MEK inhibitor, on Nf1−/− MPD [41] and Nf1−/− AML (induced by infection of Mx1-Cre, Nf1lox/lox mice [41] with a retroviral insertional mutagen, MOL407LTR) [59]. While Nf1 mutant MPD cells were not more sensitive to CI-1040 inhibition compared to WT cells, the Nf1 mutant AML cells demonstrated significant sensitivity to CI-1040 inhibition. Similarly, in vivo administration of CI-1040 to Nf1−/− mutant mice with MPD did not improve survival; however, CI-1040 treatment of mice transplanted with Nf1 mutant AML cells demonstrated significantly increased survival compared to vehicle-treated mice.

Interestingly, AML clones that demonstrated resistance to CI-1040 were found to have novel retroviral integration sites, suggesting that cooperating mutations can modulate response to CI-1040 [59].

6. Conclusions

Tremendous clinical and scientific advances have been made in JMML over the last 20 years; however, regrettably, up to 50% of JMML patients continue to succumb to this lethal malignancy. The goals continue to be improved understanding of the disease at a molecular level in an effort to identify rational therapeutic targets and efficient and successful translation of our mechanistic understanding into superior, less toxic therapeutic modalities for JMML. Furthermore, ideally, JMML will serve as a model disease leading to improved therapies for leukemias and solid tumors, in general, bearing Ras hyperactivation as a central pathogenic mechanism.

Conflict of interest

None.

Acknowledgements

This work was supported by the U.S. National Institutes of Health (5RO1HL082981-03, RJC; 3R13CA132568-02, The Office of Rare Diseases, and 5K22CA113577-03, MLL) and the Leukemia and Lymphoma Society (LLS 2157-08, MLL). MLL is a Clinical Scholar of the Leukemia Lymphoma Society. The authors gratefully acknowledge the administrative assistance of Linda S. Henson.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.leukres.2008.08.022.

References


